摘要
Introduction<br/>Recent advances in the detection of genomic DNA from plasma samples allow us to follow tumor DNA shedding in plasma during systemic treatment. Osimertinib is the standard-of-care for NSCLC patients with acquired EGFR T790M mutations. We assessed changes in serial plasma cell-free circulating tumor DNA (ctDNA) genomic alterations to predict osimertinib efficacy.<br/>Methods<br/>We prospectively collected plasma from patients having EGFR-mutated advanced NSCLC previously treated with EGFR-tyrosine kinase inhibitor therapy and with acquired EGFR T790M mutation detected by standard methods. Plasma samples were collected before starting osimertinib treatment, 4 weeks following osimertinib treatment and upon progression. CtDNA was analyzed utilizing the Guardant360 assay.<br/>Results<br/>Fifteen eligible patients received osimertinib. Before starting treatment, EGFR-activating mutations were detected in the ctDNA of all patients, and EGFR T790M was detected in 93% of the cases. Osimertinib treatment was associated with an objective response rate of 53% and a median progression-free survival of 7.3 months. Twelve of the 15 patients had undetectable plasma T790M and decreased activating mutation allelic frequency (AF) at week 4. None of the 12 patients had disease progression within 16 weeks. For the remaining 3 patients, with detectable plasma T790M (n = 2) or increased activating mutation AF (n = 1) at week 4, two had progressive disease within 16 weeks (p = 0.03).<br/>Conclusions<br/>In patients with EGFR-mutated advanced NSCLC, persistent EGFR T790M or increasing activating mutations AF as detected in ctDNA four weeks after the start of osimertinib treatment may predict disease progression within 16 weeks.
学科与关键词
- Cell-free plasma DNA-guided treatment with osimertinib in patients with advanced EGFR-mutated NSCLC.Buder Anna; Hochmair Maximilian J; Schwab Sophia; Bundalo Tatjana; Schenk Peter; Errhalt Peter; Mikes Romana E; Absenger Gudrun; Patocka Kurt; Baumgartner Bernhard; Setinek Ulrike; Burghuber Otto C; Prosch Helmut; Pirker Robert; Filipits Martin*Journal of Thoracic Oncology, 2018.
- Circulating tumor DNA analysis of EGFR -mutant non-small cell lung cancer patients receiving osimertinib following previous tyrosine kinase inhibitor treatmentJamie J. Beagan; Sander Bach; Robert A. van Boerdonk; Erik van Dijk; Erik Thunnissen; Daan van den Broek; Janneke Weiss; Geert Kazemier; D Michiel Pegtel; Idris Bahce; Bauke Ylstra; Daniëlle A.M. HeidemanLung Cancer, 2020, 145: 173-180.被引 6
- Clearing of circulating tumour DNA predicts clinical response to osimertinib in EGFR mutated lung cancer patientsEva Boysen Fynboe Ebert; Tine McCulloch; Karin Holmskov Hansen; Hanne Linnet; Boe Sorensen; Peter Meldgaard2020.
